Navigation Links
Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Date:5/19/2008

MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results of two studies on the Genomic Grade index (GGi) at the ASCO Annual Meeting, held in Chicago from May 30 to June 3, 2008. The data indicate that the Genomic Grade index predicts response to chemotherapy in breast cancer. A third study extends the pronostic utility of the GGi to inflammatory breast cancer.

The Genomic Grade index (GGi) is a 97-gene measure of tumor grade, a key prognostic indicator of breast cancer agressiveness closely related to cellular proliferation. Ipsogen is the exclusive worldwide licensee of the GGi technologies.

Two MD Anderson Cancer Center studies

In a preliminary study published in May 2008 in Breast Cancer Research (1) conducted on 133 patients, MDACC researchers had found that, among 852 genomic indexes describing biological pathways, the GGi was one of the most promising candidate for predicting response to chemotherapy.

In the first study to be presented (abstract 541, (2)), Dr. Symmans and colleagues from MDACC and Institut Bordet (Brussels, Belgium) validated the GGi as a predictive marker of chemotherapy response in 229 patients with HER2-normal breast cancer. All patients were treated with a current standard chemotherapy regimen, T/FAC (6 months of paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide) then by surgery. In such preoperative chemotherapy settings, treatment efficacy can be rapidly & precisely assessed by examining the resected tumor in a pathology laboratory.

This study concludes that high GGi is predictive for increased sensitivity to T/FAC chemotherapy in both ER- and ER+ patients. In addition, the GGi can be combined with ER and nodal status to predict which patients will not respond to preoperative T/FAC chemotherapy in 72 % of cases.

"This work demonstrates that high genomic grade, as a robust measure of proliferation in the tumor cells, is associated with benefit from chemotherapy. In the context of other published work it underlines the association between high tumoral proliferation rate and chemosensitivity, endocrine insensitivity and worse prognosis" comments Dr. Symmans, associate Professor of Pathology at the MDACC.

"This study is a straightforward demonstration of the clinical utility of the Genomic Grade index for predicting response to chemotherapy. It also highlights the ongoing commitment of the oncology community to validate new molecular assays that strongly connect with the breast tumor biology and fit within the pathologist's practices" comments Dr. Jean-Marc Le Doussal, Director of Breast Cancer Program at Ipsogen.

Visit Ipsogen booth 23128 at the 44th ASCO annual meeting

In the second study to be presented (abstract 527, (3)), Dr. Pusztai and colleagues showed a pionnering application of multi-testing on genome-wide microarrays by combining the GGi, for the prediction of chemotherapy response, with the 200-gene endocrine-sensitivity index, for the prediction of hormonotherapy response.

"This study further confirms the potential of Ipsogen's pipeline strategy of multiple high-resolution genomic measurements to improve the decision tree of chemotherapeutic options in breast cancer>> says Vincent Fert, CEO of Ipsogen. "We are fully committed to rapidly translate these clinical findings into regulatory-approved and reimbursed test offering to European and American patients," he adds.

One University of Antwerp study

A third study (abstract 11048, (4)), presented by Dr. Van Laere from Antwerp University, Belgium, validates the pronostic value of the GGi in inflammatory breast cancer, an aggressive type of breast cancer affecting a few percent of patients.

About IPSOGEN

Ipsogen is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide patients and clinicians decisions along the complex therapeutic path.

With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to revolutionary theranostics.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the US, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionnals and society in general.

Ipsogen employed 40 people as of April 30,2008. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, Connecticut, USA.

Find out more at http://www.ipsogen.com

--------------------------

(1) Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Research 2008, 10:R37.

(2) W. F. Symmans, C. Hatzis, C. Liedtke, C. Desmedt, V. Valero, H. M. Kuerer, G. N. Hortobagyi, M. Piccart-Gebhart, L. Pusztai, C. Sotiriou. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 541).

http://www.abstract.asco.org/AbstView_55_32175.html

(3) L. Pusztai, C. Hatzis, F. Cardoso, C. Sotiriou, V. Lazar, M. Piccart-Gebhart, G. N. Hortobagyi, L. van't Veer, W. F. Symmans. Combined use of genomic prognostic and treatment response predictors in breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 527).

http://www.abstract.asco.org/AbstView_55_33741.html

(4) S. J. Van Laere, G. G. Van den Eynden, I. Van der Auwera, X. B. Trinh, P. A. van Dam, E. A. Van Marck, P. B. Vermeulen, L. Y. Dirix. Inflammatory breast carcinoma signature and relapse-free survival in patients with noninflammatory breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 11048).

http://www.abstract.asco.org/AbstView_55_34698.html


'/>"/>
SOURCE Ipsogen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):